Loading clinical trials...
Loading clinical trials...
This study is to establish an accurate, robust and easily scalable COVID-19 viral nucleic acid analysis platform from, but not limited to, saliva to help enable and support contact tracing in the canton of Baselland/ Switzerland. To achieve this, crude ribonucleotide acid (RNA) extraction from saliva is validated in combination with next-generation sequencing (NGS) diagnostics and loop mediated amplification (LAMP) assays as well as point of care test (POCT) for rapid detection of viral antigens on patients' samples.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Cantonal Office of Public Health, Economics and Health Directorate, Canton Basel-Landschaft
Liestal, Switzerland
Start Date
October 24, 2020
Primary Completion Date
December 1, 2024
Completion Date
December 1, 2024
Last Updated
February 23, 2024
1,600
ESTIMATED participants
Saliva based assay: crude RNA extraction
OTHER
Validation of the NGS method
OTHER
Validation of the LAMP assays
OTHER
Validation of the POCT Antigen and Antibody tests
OTHER
Juerg Sommer, Dr.
CONTACT
Lead Sponsor
University Hospital, Basel, Switzerland
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions